# Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

> **NCT02289417** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 170 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02289417
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-08
- **Primary completion:** 2017-09-25
- **Final completion:** 2019-06-03
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289417, "Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02289417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*